Patents Examined by Bong-Sook Baek
  • Local delivery forms of acriflavine for treating tumors
    Patent number: 10195190
    Abstract: Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Henry Brem, Antonella Mangraviti, Alessandro Olivi, Betty M. Tyler, Tula Raghavan
  • Methods and compositions for ameliorating symptoms of termination of opioid pain therapy
    Patent number: 10188645
    Abstract: The disclosure is directed to a method of easing a patient's symptoms related to termination of opioid pain therapy, and compositions for achieving said method. The method and compositions comprise a series of self tapering dosages of a pharmaceutical composition that is configured to alleviate or prevent symptoms of the patient's termination of opioid pain therapy. The series of self tapering dosages may be supplied in a dosage package.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 29, 2019
    Inventors: Ian Cain Smith, Robert W. Mooney
  • Methods for treating bacterial infection
    Patent number: 10183032
    Abstract: The present disclosure relates to molecules that function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus and Streptococcus pyogenes.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 22, 2019
    Assignees: Ball State Innovation Corporation, STC.UNM
    Inventors: Susan A. McDowell, Robert E. Sammelson, Larry A. Sklar, Mark K. Haynes
  • Applications of partially and fully sulfated hyaluronan
    Patent number: 10179147
    Abstract: Described herein is the use of partially and fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof for therapeutic and cosmetic applications as well as the treatment of a number of systemic, dermatological, periodontal, ophthalmic, and urological inflammatory diseases.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: January 15, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Glenn D. Prestwich, Siam Oottamasathein, Thomas P. Kennedy
  • Method for synthesis of silica coated graphene functional hybrid material
    Patent number: 10172941
    Abstract: A process for synthesis of silica coated graphene hybrid material comprising the steps of treating graphene oxide with ammonium ions to provide ammonium-activated graphene oxide; treating the ammonium-activated graphene oxide with a solution comprising silica precursors; and silane coupling agents that comprise functional groups, to provide self-assembly of silica nanoparticles on the surface of the ammonium-activated graphene oxide and covalent bonding between the nanoparticles and the surface to provide silica coated graphene oxide; and grafting of the functional groups on the surface of the silica coated graphene oxide to provide functionalized silica coated graphene oxide; and reducing the functionalized silica coated graphene oxide to provide functionalized silica coated graphene. Silica coated graphene hybrid material obtainable by this process.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 8, 2019
    Assignee: SHT SMART HIGH-TECH AB
    Inventor: Johan Liu
  • Use of rubusoside for reducing or suppressing certain unpleasant taste impressions
    Patent number: 10165791
    Abstract: The invention relates to the use of rubusoside and certain mixtures containing rubusoside, preferably the use of certain rubusoside-containing mixtures, in particular Rubus suavissimus extracts, for masking, reducing or suppressing a bitter, sour and/or astringent taste impression. The invention further relates to orally consumable preparations, comprising at least one bitter, sour and/or astringent-tasting substance and rubusoside or certain rubusoside-containing mixtures, preferably certain Rubus suavissimus extracts, a corresponding method of producing said preparations and a method for reducing or suppressing the bitter, sour and/or astringent effect of a bitter, sour and/or astringent-tasting substance. The invention further relates to certain flavoring compositions that are particularly effective for masking, reducing or suppressing a bitter, sour and/or astringent taste impression.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: January 1, 2019
    Assignee: Symrise AG
    Inventors: Jakob Peter Ley, Katharina Reichelt, Thomas Riess, Kathrin Langer, Susanne Paetz
  • Treatment of amyotrophic lateral sclerosis
    Patent number: 10167263
    Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: January 1, 2019
    Assignees: NORTHWESTERN UNIVERSITY, CAMBRIA PHARMACEUTICALS, INC.
    Inventors: Donald R. Kirsch, Radhia Benmohamed, Anthony C. Arvanites, Richard I. Morimoto, Tian Chen, Richard B. Silverman
  • Therapeutic agent of acute myeloid leukemia containing 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-D]pyrimidine-2(1H)-one derivatives
    Patent number: 10155767
    Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 18, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae Bo Sim, Han Na Cho, Eun Hye Ju, Woo Young Hur, Ho Jong Yoon, Chi Man Song
  • TC-PTP inhibitors as APC activators for immunotherapy
    Patent number: 10150787
    Abstract: The invention encompasses the novel class of compounds represented by the Formula (I) below, which are inhibitors of the TC-PTP enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing TC-PTP mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the immunotherapeutic treatment of diseases.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: December 11, 2018
    Inventors: Michel L. Tremblay, Claudia Penafuerte, Matthew Feldhammer, George Zogopoulos, Cameron Black, Brian Kennedy
  • Dosing regimen for missed doses for long-acting injectable paliperidone esters
    Patent number: 10143693
    Abstract: The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: December 4, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Srihari Gopal, Paulien Gerarda Maria Ravenstijn, Alberto Russu, Mahesh Narain Samtani
  • Target for treating hepatitis B virus
    Patent number: 10123997
    Abstract: A method of treating hepatitis B virus includes inhibiting the activities of AKT and/or mTOR, inhibiting the synthesis of 5-phosphate ribose, and inhibiting HBV DNA and HBV cccDNA.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: November 13, 2018
    Inventor: Yong Liao
  • Cosmetic composition
    Patent number: 10117820
    Abstract: Provided is a cosmetic composition superior in antiseptic property and having high moisturizing property. A cosmetic composition containing (A) particular acylproline or a salt thereof, and (B) particular hydroxamic acid derivative, particular acetophenone derivative or diol compound.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: November 6, 2018
    Assignee: AJINOMOTO CO., INC.
    Inventors: Nana Haraya, Takanori Sugimoto, Takuya Okada
  • Virus vaccination and treatment methods with OX40 agonist compositions
    Patent number: 10106619
    Abstract: The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: October 23, 2018
    Assignee: La Jolla Institute for Allergy and Immunology
    Inventors: Michael Croft, Shahram Salek-Ardakani, Magdalini Moutaftsi, Alessandro Sette, Carl F. Ware
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects
    Patent number: 10105327
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 23, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Composition of skin external application for anti-aging
    Patent number: 10092493
    Abstract: The present invention relates to an anti-aging composition for external use on skin, and more particularly, to an anti-aging composition for external use on skin comprising at least one of catechins and flavonols as an active ingredient to inhibit decomposition and promote generation or protection at the dermis-epidermis junction.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: October 9, 2018
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Jeong Ki Kim, Hyun Jung Shin, Su Nam Kim, Byeong Gon Lee, Ih Seop Chang
  • Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
    Patent number: 10092561
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
    Patent number: 10092541
    Abstract: Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: October 9, 2018
    Assignee: Celgene Corporation
    Inventor: Robert Day
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 10092560
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: October 9, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 10092570
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: October 9, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Use of hexadeca-8,15-dienal as aroma chemical
    Patent number: 10087395
    Abstract: The present invention relates to the use of hexadeca-8,15-dienal or of a substance mixture which comprises this compound as aroma chemical, in particular as fragrance, or formulation auxiliary; and also to processes for its preparation, moreover aroma substance compositions and compositions comprising hexadeca-8,15-dienal.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 2, 2018
    Assignee: BASF SE
    Inventors: Ralf Pelzer, Frauke Thrun, Joaquim Henrique Teles, Albert Werner, Stephan Maurer